Catalyst Wire Dossier Catalyst Wire Dossier

XOLREMDI

mavorixafor · X4 Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for XOLREMDI, covering 2024-04-26 to 2026-08-20. Get the full timeline:

Most recent: EMA Authorised: Xolremdi (mavorixafor) — Norgine B.V.

See pricing